GlassScriptPhysician profile
Gail G Bryant
NPI 1447202064
$5,524.36
in general payments reported to CMS, 2019-2025
47 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $286 · 2021: $962 · 2022: $631 · 2023: $627 · 2024: $500 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,768.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $927.67 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $522.64 | 2021-2025 | |
| Pfizer INC. | $489.61 | 2019-2025 | |
| Novo Nordisk INC | $429.38 | 2019-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $398.96 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $302.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $268.80 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.27 | 2025 | Caplyta |
| Amgen INC. | $187.80 | 2020-2025 | Tavneos, Otezla, Otezla |
| Currax Pharmaceuticals LLC | $162.55 | 2020-2025 | Onzetra Xsail, Contrave |
| Astellas Pharma US INC | $152.59 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.48 | 2019-2021 | |
| Lilly USA, LLC | $128.91 | 2019-2022 | |
| Intuitive Surgical, INC. | $125.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $83.45 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.